NewLimit
Reversing biological aging with epigenetics
About NewLimit
NewLimit is developing therapies to extend human healthspan by reprogramming the epigenome — the software layer on top of DNA that controls gene expression. Backed by Brian Armstrong (Coinbase CEO), they aim to let humans live longer, healthier lives.
NewLimit website preview
Company facts
- Category
- AI
- Funding stage
- Series A
- Total raised
- $40M
- Founded
- 2021
- Team size
- 10-50
- HQ
- San Francisco
- Country
- USA
- Website
- newlimit.com
Founders of NewLimit
- Brian Armstrong
- Blake Byers
Investors backing NewLimit
- Founders Fund
- Foresite Capital
Frequently asked questions
What does NewLimit do?
NewLimit is developing therapies to extend human healthspan by reprogramming the epigenome — the software layer on top of DNA that controls gene expression. Backed by Brian Armstrong (Coinbase CEO), they aim to let humans live longer, healthier lives.
Where is NewLimit based?
NewLimit is based in San Francisco, USA.
When was NewLimit founded?
NewLimit was founded in 2021.
How much has NewLimit raised?
NewLimit has raised $40M in their Series A round.
Who founded NewLimit?
NewLimit was founded by Brian Armstrong, Blake Byers.
Who has invested in NewLimit?
NewLimit is backed by Founders Fund, Foresite Capital.